Multiple Myeloma

Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bone.

What is Multiple Myeloma?

Multiple myeloma is a form of cancer that affects the bone marrow. The cancer is also called Kahler’s disease, named after an Austrian pathologist called Otto Kahler who first described the condition.

Multiple Myeloma Epidemiology

Multiple Myeloma Treatment

Multiple Myeloma Diagnosis

Multiple Myeloma Imaging Strategies

Multiple Myeloma Symptoms

Multiple Myeloma Pathophysiology

Management of Myeloma

Latest Multiple Myeloma News and Research

Mount Sinai adopts automated data integration for oncology clinical trials

The Mount Sinai Tisch Cancer Center has transitioned its electronic health record (EHR)-to-clinical trial data integration technology from pilot to routine use across its cancer research program.

6 Oct 2026

Insurance hurdles and costs hinder access to blood cancer drugs

Patients with blood cancers often face major insurance hurdles and significant out-of-pocket costs when trying to access specialty oral anticancer medications, according to a new nationwide study led by researchers at the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2026

Ultra-low-dose radiation therapy eases painful bone lesions in multiple myeloma

A short course of ultra-low-dose radiation therapy relieved painful bone lesions from multiple myeloma for most patients in a multi-institutional phase 2 clinical trial.

27 Sep 2026

In vivo CAR-T therapy transforms customized treatments into universal medicines

A collaborative team led by Professor Huji Xu from Naval Medical University, China, together with Professors Xuanming Yang and Yujia Cai at Shanghai Jiao Tong University, China, published a comprehensive review in Volume 2, article number 33 of the journal Immunity & Inflammation on August 31, 2026.

25 Sep 2026

Optimized EAP regimen delivers outstanding mobilization effects in multiple myeloma and lymphoma patients

This prospective, multicenter phase II study was conducted across 12 medical institutions in China and registered at ClinicalTrials.gov (NCT05536154).

27 Aug 2026

Protein degrader shows strong activity against treatment-resistant blood cancers

A first-in-class therapy to target MYC, one of the most sought-after and difficult targets in cancer biology, showed promise in hard-to-treat blood cancers, according to a new preclinical study from The University of Texas MD Anderson Cancer Center published in Blood.

24 Aug 2026

AI predicts vaccine response based on pre-existing antibody patterns

Vaccines protect most people from serious illness, but the strength of that protection can vary considerably from one person to another. A new study led by Arizona State University helps us understand why.

20 Aug 2026

Aircrews face highest risk of radiation-related cancer deaths

Of more than 500 occupations in the United States, flight attendants and pilots have the highest and second-highest proportion of radiation-related cancer deaths, a new study has found.

17 Aug 2026

New gene signature predicts immunotherapy success for bone marrow cancers

A team led by researchers from the German Cancer Research Center (DKFZ), the HI-STEM Stem Cell Institute, and Medical Clinic V at Heidelberg University Hospital (UKHD) has characterized T cells in the bone marrow in cases of multiple myeloma and acute myeloid leukemia: A specific group of tumor-reactive T cells can recognize and, in principle, fight cancer cells, but is often not sufficiently activated.

10 Aug 2026

Researchers discover smart molecular glue that activates inside oxidative cancer cells

Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates.

7 Aug 2026

Scalable education program protects transplant survivors from elevated skin cancer risk

Experts at City of Hope, one of the nation's largest and most advanced cancer research and treatment organizations, are shining a spotlight on the risk of skin cancer faced by hematopoietic cell transplant (HCT) survivors, as well as the need for early detection.

6 Aug 2026

QUANTUM trial tests immune-targeting approach for primary plasma cell leukemia

The Alliance for Clinical Trials in Oncology today announced the activation of The QUANTUM Trial (Alliance A062401), a clinical study designed to test a novel, immune-targeting approach for patients newly diagnosed with primary plasma cell leukemia (PCL).

30 Jul 2026

New study redefines high risk criteria for multiple myeloma

Researchers have found that with new treatments for multiple myeloma, a serious type of blood cancer, clinicians should use different criteria for identifying patients with poor odds of survival.

20 Jul 2026

Long-term lenalidomide maintenance shows no survival advantage in multiple myeloma

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment.

16 Jul 2026

Extended myeloma maintenance therapy shows no additional survival benefit

A major national cooperative group clinical trial led by Mayo Clinic researchers found that continuing maintenance therapy with lenalidomide beyond two years after initial treatment for standard-risk multiple myeloma did not improve overall survival compared with stopping treatment after two years.

15 Jul 2026

Combination treatment strategy uses cells' waste removal functions to dismantle multiple myeloma

New research out of VCU Massey Comprehensive Cancer Center provides promising evidence for an innovative combination treatment strategy that uses cells' waste removal functions to effectively dismantle multiple myeloma.

13 Jul 2026

Scientists discover how fat tissue drives the spread of triple-negative breast cancer

Triple-negative breast cancer (TNBC) is aggressive and hard to treat. But the role of fat tissue in how the cancer spreads may help point toward new understanding and treatments, according to a new paper from scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) and colleagues at Georgetown University's Lombardi Comprehensive Cancer Center.

23 Jun 2026

New study reveals cause of chronic inflammation with age

A new study led by researchers at The University of Texas MD Anderson Cancer Center has uncovered a previously unknown connection between nucleic acid structures called R-loops and age-related inflammation – or inflammaging – that could herald new intervention options for chronic inflammation and the subsequent health conditions.

16 Jun 2026

Weight loss medications show promise in preventing obesity-related cancers

A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers.

7 Jun 2026

Teclistamab delivers deeper responses in relapsed myeloma patients

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase 3 clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

29 May 2026